Skip to main content

Xavier Martínez Gómez

Institutions of which they are part

Senior researcher
Epidemiology and Public Health
Vall Hebron Institut de Recerca

Xavier Martínez Gómez

Institutions of which they are part

Senior researcher
Epidemiology and Public Health
Vall Hebron Institut de Recerca

Research lines

Vaccines

The group has participated in different phase II, III and IV clinical trials focused on the study of the immunogenicity, efficacy and safety of several preventive vaccines (e.g. influenza, human papilloma virus, hepatitis B, herpes zoster, respiratory syncytial virus…).

Currently, our group has expanded its line of research on the adjuvanted recombinant Herpes Zoster vaccine testing its safety and immunogenicity in pediatric immunosuppressed patients and adults =50 years of age with a prior episode of Herpes Zoster. Regarding observational studies, the group is leading a population study about the incidence of herpes zoster by risk groups (PI15/02273).

Our team has also started a new line of investigation for a Respiratory Syncytial Virus vaccine in healthy pregnant women.

IP: Xavier Martínez Gómez

Projects

ESTUDIO DEL PAPEL DE LA CENTRALIZACIÓN DEL DIAGNÓSTICO ANATOMOPATOLÓGICO Y LA APLICACIÓN DE ESTRATÉGIAS DE MEDICINA DE PRECISIÓN EN SARCOMAS

IP: Cleofé Romagosa Pérez-Portabell
Collaborators: Xavier Martínez Gómez, Ximena Garcia Torres
Funding agency: Asociación Española Contra el Cáncer
Funding: 270130
Reference: ECAEC222952DEAL
Duration: 01/12/2022 - 30/11/2027

INCIDENCIA Y HOSPITALIZACIÓN POR HERPES ZÓSTER EN CATALUÑA ENTRE 2007 Y 2017

IP: INCIDENCIA Y HOSPITALIZACIÓN POR HERPES ZÓSTER EN CATALUÑA ENTRE 2007 Y 2017
Collaborators: Xavier Martínez Gómez, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma
Funding agency: Instituto de Salud Carlos III
Funding: 24926
Reference: PI15/02273
Duration: 01/01/2016 - 30/11/2020

Development of a universal inFLUenza vaccine based on Tandem CORE technology (FLUTCORE) Grant Agreement nº 602437

IP: Development of a universal inFLUenza vaccine based on Tandem CORE technology (FLUTCORE) Grant Agreement nº 602437
Collaborators: Jose Angel Rodrigo Pendás, Susana Otero Romero, Xavier Martínez Gómez, Tomàs Pumarola Suñé, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma
Funding agency: EUROPEAN COMMISSION
Funding: 81420
Reference: FLUTCORE_FP7HEALTH2013
Duration: 01/09/2013 - 31/03/2017

Aticuerpos antitransglutaminasa en biopsias musculares de pacientes con miopía inflamatoria

IP: Albert Selva O'Callaghan
Collaborators: Moisés Labrador Horrillo, Ernesto Trallero Araguas, Xavier Martínez Gómez
Funding agency: Instituto de Salud Carlos III
Funding: 33880
Reference: PI080450
Duration: 01/01/2009 - 31/12/2011

Related news

On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.

Related professionals

Maria Teresa Mateu Peláez

Maria Teresa Mateu Peláez

Predoctoral researcher
Headache and Neurological Pain
Read more
Xavier Cañas Perea

Xavier Cañas Perea

Director/a d'Àrea
Clinical Research Development Directorate
Read more
Luca Bollo

Luca Bollo

Predoctoral researcher
Clinical Neuroimmunology
Read more
Sabrina Ayelen Gatti

Sabrina Ayelen Gatti

Predoctoral researcher
Neurodegenerative Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.